(Q46797000)

25 December 2017

title

Use of cyclophosphamide in azathioprine failures in pemphigus (English)

1 reference

25 December 2017

1 reference

Ahmed AR

1

1 reference

25 December 2017

Hombal S

series ordinal

2

1 reference

25 December 2017

language of work or name

English

0 references

publication date

1 September 1987

1 reference

25 December 2017

Journal of the American Academy of Dermatology

published in

1 reference

25 December 2017

volume

17

1 reference

25 December 2017

issue

3

1 reference

25 December 2017

page(s)

437-442

1 reference

25 December 2017

International mortality from bullous diseases since 1950.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2887%2970226-6

7 January 2021

Pemphigus: current concepts

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2887%2970226-6

7 January 2021

Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2887%2970226-6

7 January 2021

Treatment of pemphigus with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2887%2970226-6

7 January 2021

Successful use of cyclophosphamide and prednisone for initial treatment of pemphigus vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2887%2970226-6

7 January 2021

Cyclophosphamide in the treatment of pemphigus vulgaris and bullous pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2887%2970226-6

7 January 2021

Azathioprine for pemphigus and pemphigoid--a 4 year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2887%2970226-6

7 January 2021

Treatment of pemphigus and pemphigoid with azathioprine.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2887%2970226-6

7 January 2021

Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2887%2970226-6

7 January 2021

Immunosuppressants in the treatment of pemphigus

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2887%2970226-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0190-9622%2887%2970226-6

1 reference

7 January 2021

Pemphigus vulgaris successfully treated with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2887%2970226-6

7 January 2021

Pemphigus Vulgaris Treated With Cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2887%2970226-6

7 January 2021

Treatment of pemphigus with corticosteroids and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2887%2970226-6

7 January 2021

Pemphigus controlled by dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2887%2970226-6

7 January 2021

Pemphigus controlled by sulphapyridine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2887%2970226-6

7 January 2021

Dapsone in the Treatment of Pemphigus Vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2887%2970226-6

7 January 2021

Treatment of pemphigus vulgaris. Results obtained in 84 patients between 1961 and 1982.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2887%2970226-6

7 January 2021

Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2887%2970226-6

7 January 2021

10.1016/S0190-9622(87)70226-6

Identifiers

DOI

1 reference

25 December 2017

1 reference

25 December 2017